Welcome to our dedicated page for Tenax Therapeutics SEC filings (Ticker: TENX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenax Therapeutics filings document a Phase 3, development-stage pharmaceutical company developing cardiopulmonary therapies, including TNX-103 (oral levosimendan) for PH-HFpEF. Recent 8-K reports record financial results, clinical program updates for LEVEL and LEVEL-2, intellectual-property notices, and amendments to levosimendan license rights, including expanded worldwide rights for orally administered products.
Proxy and current-report filings also describe Nasdaq-listed common stock, executive appointments, employment and compensation arrangements, equity awards, governance matters, and named-executive pay disclosures. These records frame the company's capital structure, leadership responsibilities, material agreements, and clinical-stage operations around levosimendan development and commercialization rights.
Tenax Therapeutics director Michael H. Davidson reported a new equity award and his current holdings in company securities. On 01/09/2026, he was granted a stock option to buy 30,000 shares of Tenax Therapeutics common stock at an exercise price of $13.3 per share, expiring on 01/09/2036. Following this grant, he holds 2,881 shares of common stock directly.
He also reports several existing derivative positions, including stock options covering 100,000 shares exercisable from 12/10/2025 to 12/10/2034, and options for 80,000 shares exercisable from 07/01/2026 to 07/01/2035, plus smaller option positions. In addition, he holds a pre-funded warrant for 47,500 shares with a $0.01 exercise price and no expiration date, and a warrant for 25,000 shares with a $4.5 exercise price that can terminate based on Phase 3 LEVEL Study topline data timing or on August 8, 2029.
Tenax Therapeutics CEO Christopher Thomas Giordano received a grant of 450,000 stock options on January 9, 2026. The options give him the right to buy common stock at an exercise price of $13.3 per share.
According to the vesting terms, 25% of the underlying shares vest and become exercisable on January 9, 2027, and the remaining shares vest in equal monthly installments over the following 36 months, subject to his continued employment. After this grant, he directly holds 2,605 shares of common stock and several other stock option awards with various expiration dates extending through 2035.
Tenax Therapeutics, Inc. reported a new equity award to its chief medical officer and director, Stuart Rich. On January 9, 2026, he received a grant of stock options to buy 250,000 shares of common stock at an exercise price of $13.3 per share. These options vest over time, with 25% becoming exercisable on January 9, 2027 and the remaining shares vesting in equal monthly installments over the following 36 months, conditioned on his continued employment.
After this grant, he holds 5,266 shares of common stock directly, plus additional shares held indirectly through several family trusts. The filing states that he has voting or trustee roles with these trusts but disclaims beneficial ownership of their shares except to the extent of any pecuniary interest.
Tenax Therapeutics director Gerald T. Proehl reported an equity award and updated holdings. On January 9, 2026, he received a stock option to buy 30,000 shares of common stock, representing 3,000 derivative securities acquired, with an exercise price of $13.30 per share and an expiration date of January 9, 2036.
After this grant, he directly holds 1,667 shares of common stock, stock options covering 30,000, 100,000 and 80,000 shares under various prior grants, and a pre-funded warrant for 31,654 shares with a $0.01 exercise price and no expiration date. He also holds a warrant for 16,660 shares at a $4.50 exercise price that will expire based on the timing of topline data from Tenax’s Phase 3 LEVEL Study or, at the latest, on August 8, 2029.
Tenax Therapeutics director June Sherie Almenoff reported a new stock option grant and her current equity holdings in a Form 4 filing. On January 9, 2026, she was granted a stock option for 30,000 shares of common stock at an exercise price of $13.30 per share. This option becomes exercisable on January 9, 2027 and expires on January 9, 2036, and was reported as held directly.
The filing also lists previously awarded stock options held directly, covering 100,000 shares (exercisable from December 10, 2025 to December 10, 2034), 80,000 shares (exercisable from July 1, 2026 to July 1, 2035), and two very small option positions of 4 shares each. In addition, 1,993 shares of common stock are reported as held indirectly through Meadowlark Management, LLC, with a statement that Almenoff disclaims beneficial ownership except to the extent of her pecuniary interest.
Tenax Therapeutics director Declan Doogan reported a new stock option grant. The Form 4 shows that on 01/09/2026 he received a stock option to buy 30,000 shares of Tenax common stock at an exercise price of $13.3 per share. The option is shown as exercisable on 01/09/2027 and expiring on 01/09/2036, and is held directly.
In addition to this grant, the filing lists previously awarded stock options covering 100,000 shares exercisable from 12/10/2025 and 80,000 shares exercisable from 07/01/2026, along with two very small option positions of 4 shares each. Doogan also directly holds 2,274 shares of Tenax common stock following the reported transactions.
Tenax Therapeutics director Robyn Hunter reported a new stock option grant in a Form 4 filing. On January 9, 2026, Hunter received stock options to buy 30,000 shares of common stock at an exercise price of $13.30 per share, with no cash paid for the option itself.
The options become exercisable on January 9, 2027 and expire on January 9, 2036. After this grant, Hunter directly holds 30,000 of these newly reported derivative securities, alongside other previously granted stock options in Tenax Therapeutics.
Tenax Therapeutics, Inc. reported an update to the employment terms of its Chief Medical Officer, Dr. Stuart Rich. Effective January 1, 2026, Dr. Rich will devote an average of four days per week to his duties as Chief Medical Officer under a second amendment to his Executive Employment Agreement.
His annual base salary will be prorated to reflect this modified work schedule. The amendment was approved by the Board of Directors on December 22, 2025, and formally entered into on January 6, 2026. The complete terms are set out in the Second Amendment to Executive Employment Agreement, filed as Exhibit 10.1.
Tenax Therapeutics reported new clinical progress for its lead drug candidate TNX-103 in patients with pulmonary hypertension related to heart failure with preserved ejection fraction. A planned blinded sample size re-estimation for the LEVEL Phase 3 trial showed the study is powered at well over 90% to detect a 25 meter change in 6-minute walk distance, the primary measure of effectiveness. This supports keeping the existing enrollment target and previously communicated timelines for finishing enrollment and reporting topline data. Tenax also started LEVEL-2, a second global Phase 3 registrational trial of TNX-103 in the same patient population, indicating a broader late-stage development program.
Tenax Therapeutics, Inc. director and Chief Medical Officer reported recent open-market purchases of the company’s common stock and detailed his equity holdings. On December 2, 2025, he bought 1,000 shares at a weighted average price of $9.0059, followed by 1,500 shares at $9.0786 on December 3 and 2,500 shares at $9.1992 on December 4.
After these transactions he directly owns 2,766 common shares and has additional indirect holdings of 2,500, 1,194, and 1,194 shares through specified family trusts, for which he disclaims beneficial ownership beyond his pecuniary interest. He also beneficially owns stock options over 157, 63, 119, 500,000, and 625,000 shares at stated exercise prices, with vesting tied to time-based schedules and milestones such as a Phase 3 clinical trial, FDA-related steps, and continued employment.